Multi-Targeted Mechanisms Underlying the Endothelial Protective Effects of the Diabetic-Safe Sweetener Erythritol

Daniëlle M. P. H. J. Boesten¹*, Alvin Berger²*, Peter de Cock³, Hua Dong⁴, Bruce D. Hammock⁴, Gertjan J. M. den Hartog¹, Aalt Bast¹

¹ Department of Toxicology, Maastricht University, Maastricht, The Netherlands, ² Global Food Research, Cargill, Wayzata, Minnesota, United States of America, ³ Cargill RandD Center Europe, Vilvoorde, Belgium, ⁴ Department of Entomology and UCD Comprehensive Cancer Center, University of California Davis, Davis, California, United States of America

Abstract

Diabetes is characterized by hyperglycemia and development of vascular pathology. Endothelial cell dysfunction is a starting point for pathogenesis of vascular complications in diabetes. We previously showed the polyol erythritol to be a hydroxyl radical scavenger preventing endothelial cell dysfunction onset in diabetic rats. To unravel mechanisms, other than scavenging of radicals, by which erythritol mediates this protective effect, we evaluated effects of erythritol in endothelial cells exposed to normal (7 mM) and high glucose (30 mM) or diabetic stressors (e.g. SIN-1) using targeted and transcriptomic approaches. This study demonstrates that erythritol (i.e. under non-diabetic conditions) has minimal effects on endothelial cells. However, under hyperglycemic conditions erythritol protected endothelial cells against cell death induced by diabetic stressors (i.e. high glucose and peroxynitrite). Also a number of harmful effects caused by high glucose, e.g. increased nitric oxide release, are reversed. Additionally, total transcriptome analysis indicated that biological processes induced by diabetic stressors (i.e. high glucose and peroxynitrite) are differentially regulated due to high glucose are corrected by erythritol. We conclude that erythritol protects endothelial cells during high glucose conditions via effects on multiple targets. Overall, these data indicate a therapeutically important endothelial protective effect of erythritol under hyperglycemic conditions.

Introduction

Chronic hyperglycemia in diabetes is associated with cardiovascular disease and microvascular pathologies in the retina, kidney and peripheral nerves [1,2]. Most of these diabetic complications find their origin in damaging of the endothelium, a layer of cells lining the cardiovascular system [3,4,5]. The endothelium participates in numerous normal physiological functions including control of vasomotor tone, maintenance of blood fluidity, regulation of permeability, formation of new blood vessels and trafficking of cells. The endothelium also plays an important role in several human diseases. During inflammation, genes become activated within the endothelium to facilitate recruitment, attachment, and transmigration of inflammatory cells. In chronic inflammatory diseases, endothelial cell responses become impaired, leading to endothelial dysfunction (ED) [1,6].

Erythritol (1,2,3,4-butanetetrol; ERT) is a natural C4 polyol that has a sweetness of 60–80% that of sucrose. More than 90% of ingested ERT is not metabolized by humans and excreted unchanged in urine, indicating ERT is efficiently absorbed not metabolized for energy and excreted by renal processes [7,8]. It is a suitable bulk sweetener because it is not metabolized, does not influence blood glucose or insulin levels and does not cause caries [9,10], consequently it is also safe for diabetics.

We have previously shown that ERT is an excellent hydroxyl radical scavenger in vitro and that it also delayed radical-induced hemolysis in red blood cells [11]. Supplementation with ERT reduced lipid peroxidation [8] and prevented loss of endothelium-dependent vasorelaxation in a diabetic rat model [11]. Given the importance of the endothelium in regulating vascular function and initiation and propagation of inflammatory responses to high glucose, herein, we, extend our previous studies with rats [11], by evaluating effects of ERT in an endothelial cell line exposed to normal and high glucose concentrations, using targeted and transcriptomic approaches.
Materials and Methods

Chemicals

Erythritol was kindly provided by Cargill (ViÅ°voorde, Belgium). F12K medium and fetal calf serum (FCS) were obtained from ATCC (Wesel, Germany). Penicillin/streptomycin, Hank’s Balanced Salt Solution (HBSS) and trypsin were purchased from Gibco (Breda, The Netherlands). Glucose, N’4-nitro-L-arginine methyl ester (L-NAME), 2-thiobarbituric acid (TBA), phosphoric acid, Ethylene diamine tetraacetic acid (EDTA), butylated hydroxytoluene (BHT), ethylene glycol tetraacetic acid (EGTA), nuclease P1, alkaline phosphatase, calcium ionophor A23187 and 4,5-diaminofluorescein diacetate (DAF-2) were obtained from Sigma Aldrich (Steinheim, Germany). 3-morpholinophosphinodinitroimidazole (SIN-1) was acquired from Alexis Biochemicals (San Diego, CA, USA). Endothelial cell growth supplement (ECGS) was obtained from BD Bioscience (Breda, The Netherlands). Heparin was purchased from Leo Pharmaceuticals (Amsterdam, The Netherlands). 3-morpholino-sydnonimine (L-NAME) was obtained from Perkin Elmer (Waltham, MA, USA).

Cell Culture

Human umbilical vein endothelial (HUVEC) cells were obtained from ATCC. HUVECs were cultured in F12K medium with 10% non-heat inactivated FCS, 1% penicillin/streptomycin, 0.05 mg/ml ECGS and 0.1 mg/ml heparin. Cells were maintained in collagen coated T75 flasks (Greiner Bio-one, Alphen a/d Rijn, The Netherlands) at 37°C in a 5% CO2 atmosphere. For experiments, cells were seeded in 6 well plates/T75 flasks and grown until 80% confluency. Next, medium was removed and cells were washed with HBSS. New medium without supplements and erythritol (final concentration 5 mM), L-NAME (final concentration 0.1 mM or 0.5 mM) or vehicle solution (medium) was added to the cells. After 1 hour incubation glucose (final concentration 30 mM glucose) or vehicle (medium) was added to the cells. Subsequently, cells were incubated for 24 hours. The same protocol was used for incubation with SIN-1 (final concentration 0.5 mM).

Cell viability

HUVEC cells were grown in 6 well plates until 80% confluence. After incubation medium was removed and the cells were washed with HBSS and harvested with trypsin. All cell material including medium and HBSS was collected and centrifuged (3 minutes, 500xg) and used to determine viability of the cells using the trypan blue exclusion assay. The percentage of dead cells was calculated with the formula: (dead cells/dead cells + viable cells) * 100%.

Malondialdehyde measurement

Malondialdehyde (MDA) was measured with HPLC. Briefly, 100 μl of cell lysate or MDA standard were mixed with 1 ml of reagent, composed of 10 parts reagent A (12 mM TBA, 0.32 M phosphoric acid and 0.01 mM EDTA) and one part of reagent B (1.5 mg/ml BHT in ethanol). Samples and standards were heated for 1 hour at 99°C. After cooling, 500 μl of butanol was added and samples and standards were centrifuged for 5 minutes at maximum speed to extract the TBA-MDA product. Ten μl of the extract was injected on to an Altima HP C18 column (Grace, Breda, The Netherlands) and eluted with 65% water and 35% methanol with 0.1% trifluoroacetic acid. Fluorescence was recorded at λex 532 nm/λem 553 nm. MDA concentration was determined by calculating the peak height of the TBA-MDA product and results were corrected for protein content of the lysates.

Protein carbonyl measurement

Cell lysates were monitored for their protein carbonyl contents using the protein carbonyl assay kit (Cayman Chemical, Ann Arbor, MI, USA). 2,4-Dinitrophenylhydrazine (DNPH) reacted with protein carbonyls in the lysate. The amount of proteinhydrozone produced was then quantified spectrophotometrically at an absorbance of 358 nm. The carbonyl content was corrected for protein content of the lysates.

8-Hydroxydeoxyguanosine measurement

DNA was extracted from HUVEC cells using the QIAamp DNA Mini Kit (Qiagen, Venlo, The Netherlands) according to the manufacturer's protocol and quantified spectrophotometrically. After extraction, 15 μg DNA was digested into deoxyribonucleosides by treatment with nuclease P1 (0.02 U/μl) and alkaline phosphatase (0.014 U/μl). To measure oxidative damage of DNA by 8-OHdG the Bioxytech 8-OHdG-EIA kit (Oxis Health products, Beverly Hills, CA, USA) was used. Digested samples were added to the microtiter plate precoated with 8-OHdG and the assay was performed according to the manufacturer's instructions.

NOS3 activity

NOS3 activity was determined as described previously [12,13,14] using the NOS activity assay kit from Cayman. NOS3 activity was determined in cell pellets which were homogenized in ice-cold 25 mM Tris-HCl buffer containing 1 mM EDTA and 1 mM EGTA. Next, 22 μM [3H]-arginine (specific activity: 43 Ci/mmol) and 1 mM calcium chloride, 6 μM tetralinhydrocarboxylic acid, 2 μM flavin adenine mononucleotide and 1 mM of reduced nicotinamide dinucleotide phosphate as cofactors was added to the homogenate. After 60 minutes incubation at room temperature, the reaction was stopped by adding a slightly acidic HEPES buffer containing a calcium ion chelator. [3H]-arginine was separated from [3H]-citrulline by DOWEX ion exchange resin. Scintillation fluid was added and samples were counted for 5 minutes in a Wallac Liquid Scintillation counter. Background counts were determined by adding [3H]-arginine to the DOWEX resin and determining the remaining counts. Total counts were obtained by adding [3H]-arginine to the HEPES buffer and determining the counts. NOS3 activity was then determined by calculating the conversion percentage by % conversion = ([dpm reaction - dpm background]/dpm total)×100 after which the formed amount of [3H]-citrulline could be calculated. This value was then transformed into units of NOS3 activity per milligram protein. (1 unit = 1 micromole of citrulline per minute).

Nitric oxide release

Quantification of nitric oxide (NO) released by the HUVEC was performed by using the DAF-2 fluorescence assay as described by Rathel et al [15]. HUVECs were grown in 6 well plates until 80% confluence. After incubation cells were washed twice with PBS + Ca2+. Subsequently, cells were incubated with PBS + Ca2+ containing 100 μM L-arginine for 10 minutes at 37°C. Afterwards, the calcium ionophor A23187 and DAF-2 were added into the buffer at final concentrations of respectively 1 μM and 0.1 μM. Next, cells were incubated in the dark for another 30 minutes at 37°C. Cell supernatants were then transferred into an opaque 96 well and fluorescence was measured on a
spectrophotometrically using a NanoDrop. RNA quality was further assessed by automated gel electrophoresis on an Agilent 2100 Bioanalyzer (Agilent Technologies, Amstelveen, The Netherlands). All samples were found to be pure and free of RNA degradation. Sample preparation, hybridization, washing, staining and scanning of the Affymetrix Human Genome U133 Plus 2.0 GeneChip arrays (Affymetrix, Santa Clara, CA, USA) were conducted according to the manufacturer’s manual. Quality controls were within accepted limits.

Data processing and statistical analysis
Microarray data was processed using R and packages from the Bioconductor repository, including affy [19,20,21]. Probe sets and annotations were updated using the Entrez Gene based re-annotation by the BrainArray group [22]. The tMAMA algorithm was used to obtain background corrected, normalized, and log-transformed intensities for each probe set [23]. Genes that had low intensity signals (2log 100) on each array were removed before further processing. Determination of differentially expressed genes between relevant experimental groups was performed using the R limma package [24]. Regression models were built correcting for the day of the run and including an interaction term between ERT treatment status and glucose level.

Statistical analysis
For all analyses, p-values were calculated for the following comparisons: HGERT vs. HG (HGERT/HG); NGERT vs. NG (NGERT/NG); and HG vs. NG (HG/NG) (HG, high glucose; NG, normal glucose). For targeted analyses, there were 3 replications and data were evaluated by ANOVA models and student’s t-tests for each of the above three comparisons. P-values <0.05 were considered statistically significant. P-values<0.1 were considered statistical trends, and are also described, since sample sizes were small (typically n = 3), and in some cases, assay variation was high.

Results
Erythritol attenuates glucose induced cell death
The effect of incubating HUVECs with HG, ERT or a combination of ERT and glucose (HGERT) was investigated by evaluating the cell viability using the trypan blue exclusion assay. When HUVECs were incubated with HG for 24 hours the percentage of death cells increased almost 4-fold (p = 0.0002) without affecting total cell number (Figure 1). Addition of ERT or the nitric oxide synthase (NOS) inhibitor L-NAME (0.1 mM or 0.5 mM) completely prevented this increase in the percentage of dead cells (p = 0.002 for ERT; p = 0.003 and p = 0.001 for L-NAME). Longer HG incubation (48 hours) resulted in a dramatically lower total cell number (inset figure 1C). Incubation for 24 hours with the peroxynitrite-generating compound SIN-1 also significantly increased cell death which was attenuated by addition of 3 mM ERT (p = 0.03 and p = 0.06). Moreover, under normal glucose conditions incubation with ERT did not result in an increased cell death compared to incubation without ERT.
Effects on oxidative stress parameters

Because hyperglycemia is strongly associated with oxidative stress, we investigated three parameters of oxidative stress. Firstly, the protein carbonyl content of the HUVECs was measured. Protein carbonyls are products of the reaction between proteins and reactive oxygen species. Though not significant, a trend toward higher carbonyl content visible after incubation with HG compared to NG incubation for 24 hours (figure 2B). Addition of 5 mM ERT showed a trend toward a lower protein carbonyl content (p = 0.09). Next, the amount of malondialdehyde (MDA) in HUVECs was assessed. MDA is one of the end products of lipid peroxidation, a chain reaction in membrane lipids initiated by reactive oxygen species. Figure 2A indicates that incubation with 5 mM ERT, HG and HGERT does not increase the amount of MDA compared with HUVECs incubated with NG. Finally, the amount of oxidized nucleotide, in the form of 8-hydroxydeoxyguanosine (8-OHdG) was determined. Incubation with HG for 24 hours did not increase the amount of 8-OHdG (figure 2C). Furthermore, incubation with 5 mM ERT with either NG or HG did not have an effect on the amount of 8-OHdG in HUVECs.

Effects on endothelial function

Production of the vasoactive gaseous radical nitric oxide (NO) by NOS is one of the most important functions of the endothelium. In the endothelium this is predominantly the NOS3 isoform [3,26]. Therefore, we investigated the production of NO by HUVECs, which is shown in Figure 3A. When HUVECs were exposed to HG for 24 hours a 3-fold increase in NO release was observed (p = 0.04). Pre/coincubation with ERT showed a trend toward lower NO production (p = 0.06) compared to HG alone. Additionally, we looked at the effect of ERT on NOS3 activity in lysates from HUVECs exposed to HG (figure 3B). No difference between the conditions was observed. High variability (either biological or assay specific) may have prevented changes from being statistically different. Figure 3C shows an increase in gene expression of NOS3 after 24 hours under HG conditions (p = 0.03), which was attenuated by ERT (p = 0.1).

Eicosanoid analysis

Eicosanoids formed from polyunsaturated fatty acids via classical cyclooxygenase and lipoxygenase pathways, as well as P450-derived epoxycosatetraenic acids (EETs) formed via soluble epoxide hydrolase (sEH) were measured in both cell pellets and culture medium (Figure 4 and table S1). Thromboxane B2 (TXB2) was increased in pellets of cells exposed to HGERT compared to HG alone in pellets (p = 0.03). Both 8-HETE (p = 0.05) and 12-HETE (p = 0.03) were decreased in pellets from cells exposed to HGERT compared to HG alone. In supernatants we only found a decrease of excretion of 14,15-DiHETrE by cells exposed to HGERT compared to cells exposed to only HG (p = 0.04). Cells incubated with ERT excreted more 12,13-DiHOME (p = 0.01) and showed a trend towards less prostaglandin E2 (pGE2; p = 0.06) and prostaglandin D2 (pGD2; p = 0.05) excretion compared to cells incubated without ERT.

Transcriptomic analysis

The numbers and overlap of transcripts changed in response to three comparisons are shown by Venn diagram (Figure 5). ERT induced small but significant fold changes in many transcripts. Maximum fold changes for down regulation were 0.94–0.97; and for up regulation were 1.04–1.13. There were 521 transcripts
changed in response to HGERT vs. HG (HGERT/HG; \( p < 0.05 \)). Numbers of transcripts down- and up regulated was similar (296 down, 225 up). Comparing NGERT to NG (NGERT/NG), 194 transcripts changed. Only 6 transcripts changed in common for HGERT/HG and NGERT/NG, often with a different directionality, and did not change in response to HG/NG. Without ERT, HG alone (HG/NG) altered 434 transcripts. A striking observation was that under HG conditions, ERT reversed direction of change in 148 of the 153 transcripts changing in common with HGERT/HG and HG/NG, suggesting potential benefits of using ERT to ameliorate pathologies associated with hyperglycemia (figure 6). A subset of transcripts (368) were uniquely affected by HGERT/HG and HG/NG alone (HG/NG).

Discussion

With this study we want to identify the mechanism(s) by which ERT exerts its endothelium-protective effect during diabetic stress, previously demonstrated in a diabetic rat model [11]. Hydroxyl radical scavenging by ERT alone cannot explain the powerful \textit{in vivo} protective effects. Therefore the potential protective effects of ERT were investigated in different areas via targeted (e.g. cell viability, oxidative stress parameters, endothelial function parameters) and transcriptomic profiling in HUVECs. This cell line was chosen as a model because it has been used in a number of scientific studies into vascular inflammation, endothelial dysfunction and effects of hyperglycemia [27,28,29,30,31].

The induction of apoptotic endothelial cell death by HG has often been described [32,33] and is highly implicated in the development of diabetic complications. We showed that exposure of HUVECs to HG increased the number of dead cells, which could be prevented by ERT. This higher number of death cells under HG conditions seems to be caused by an increase in NO, because addition of the NO inhibitor L-NAME under HG conditions decreased the amount of death cells. The involvement of NO in glucose toxicity has been described previously [34,35,36]. Another indication of the involvement of NO in endothelial cell death was found when HUVECs were incubated with the peroxynitrite generator SIN-1. We showed that SIN-1 induced cell death, which was attenuated by ERT. Specifically for endothelial cells during diabetes, this is an important finding since peroxynitrite formation is likely to be increased during diabetes. Peroxynitrite is generated by the reaction of superoxide radicals with nitric oxide [37], the production of these precursors is known to be increased during diabetes [38,39]. Peroxynitrite can induce lipid peroxidation and protein nitrosylation and thus plays a role in diabetes related tissue damage [40]. In a previous study, ERT was shown to have peroxynitrite scavenging activity in an \textit{in vitro} system [41].

Subsequently, we looked at the ability of ERT to reduce oxidative damage caused by HG in HUVECs. Many studies have demonstrated that hyperglycemia triggers oxidative stress and generation of free radicals [1,33,42,43]. These radicals cause damage to membranes, proteins and DNA resulting in cellular dysfunction and death. Radical scavenging by ERT reduces damage which may contribute to its endothelial protective effect. In HUVECs exposure to HG resulted in higher protein carbonyl levels while MDA and 8OHdG levels were not increased. This indicates that oxidative damage in HUVECs due to HG is concentrated in the cytosol. Since the majority of the proteins in the cell are located in the cytosol and therefore in the vicinity of the source of the high-glucose-induced oxygen radicals, it is likely that oxidative damage will probably be noted first as oxidized proteins as we observed with these results.

ERT did not affect NOS3 activity in HUVECs. Remarkably, the release of nitric oxide and the expression of the NOS3 gene were increased after incubation with high glucose only. This is in perfect agreement with the observation of Pandolfi and many others, who observed that HUVECs from human and animal origin, display increased NO production and NOS3 gene expression [39,44]. How this relates to endothelial dysfunction, which is commonly regarded to be the result of impaired NO production, is currently unknown, although it has been suggested that the increased NO levels influence the transcription of genes that affect adenosine uptake by endothelial cells [39].

Eicosanoids are potent inflammatory mediators triggered by oxidative stress and/or hyperglycemia. Even small changes in amount of these bioactive molecules could be biologically important. Differences in concentration of TXB\textsubscript{2}, 8-HETE and 12-HETE were observed in cell pellets. Especially the decrease of 12-HETE in presence of ERT is of interest since it is a pro-inflammatory molecule produced from arachidonic acid via 12-lipoxygenase (12-LO) [45]. Oxidative stress and HG incubations of endothelial cells have been shown to increase 12-HETE and diabetic pigs with elevated blood glucose have increased 12-HETE [46]. In monocytes, HG increased 12-HETE and monococyte adhesion to endothelial cells via monocyte production of integrins [47]. In endothelial cells, 12-HETE induced integrin production in a PKC-dependent manner [48]. Exposure of endothelial cells to 12-HETE decreased production of vasodilatory PGI\textsubscript{2} [49]. In culture medium we found differences in 14,15-DiHETE which is produced from arachidonic acid via Cyp 2C and 2J to form EETs, which are in turn converted to DiHETE via \textit{sEH}. The decrease in 14,15-DiHETE we found is consistent with HG suppression of \textit{sEH} [50], resulting in increased EETs and EET-induced vasodilatation. EETs were not observed to be increased in our system. Comparing ERT exposed cells to non-ERT exposed cells we also found some differences in the supernatants between

---

**Figure 2. Effect on oxidative stress parameters.** Effect of pre/co incubation with 5 mM erythritol (ERT) on HUVECs cultured in normal glucose (NG, 7 mM) or high glucose (HG, 30 mM) for 24 hours on malondialdehyde (A), carbonyl (B) and 8-OHdG (C) content. Data are expressed as means \pm standard error of three independent experiments. \( \# = p<0.1 \) compared to HG.

doi:10.1371/journal.pone.0065741.g002
molecules involved in mitochondrial dysfunction (12,13-DiHOME) and vasodilation and inflammation (PGE2 and PGD2) [51]. These findings indicate that various biologically important eicosanoids may mediate ERT effects under both NG and HG conditions in HUVEC cells.

To explore how ERT affected HUVECs on a transcriptional level we performed microarray analysis. We found several transcripts related to endothelial function to be altered when comparing HG to NG incubations including Bmp4, Vegfc and...
Ccl2 (Table 1). Bmp4 is a member of the bone morphogenetic protein family, which is a part of the TGFβ superfamily of growth and differentiation factors. In endothelial cells, BMP4 produces a pro-inflammatory gene product inducing icam-1 and monocyte adhesion via NFκB signaling [52]. When overexpressed, BMP4 may contribute to endothelial dysfunction, promoting ROS production and apoptosis [53]. Vegfc is a PDGF/VEGF family member with roles in angiogenesis and endothelial cell growth. Ccl2 transcribes a chemotactic factor attracting monocytes and basophils. Other transcripts are involved in endothelial aggregation (pear1 [54]) and vasodilation (edn1). Also, HGERT and HG comparisons resulted in altered transcripts linked to endothelial function. These transcripts were involved in apoptosis (bmp6, highly expressed in HUVECs [55]), focal adhesion (jup, foxc1, krit1), differentiation and proliferation (notch1).

Transcripts related to apoptosis are shown in Table 2. Under HG, ERT signalled via numerous pro- and anti-apoptotic pathways. As ERT protects endothelial cells from cell death
under HG conditions (figure 1A), it seems that ERT has anti-apoptotic effects and that post translational modifications of transcribed proteins and dimerization events may explain why pro-apoptotic transcriptomic changes seem to have occurred (Table 2).

Over-represented canonical pathways included (table 3): tricarboxylic acid cycle (TCA) cycle, TGF beta signaling pathway, glutathione metabolism and glucuronidation. Noncanonical networks included PIK3R1, NFκB, HNF, XBP1, SOS, and RELA. These canonical and non-canonical pathways are linked to

| Table 1. Altered transcripts with a link to endothelial function. |
|---------------------------------|----------------|----------------|
| **Entrez gene name**          | **Transcript** | **HGERT/HG** |
| Chemokine (C-C motif) ligand 2 | ccl2           | 1.04          |
| Endothelin 1                   | edn1           | 0.99          |
| Endoglin                       | eng            | 1.01 0.98     |
| Forkhead box C1                | foxc1          | 1.01          |
| Growth factor receptor-bound protein 10 | grb10 | 0.99 |
| KRT1, ankyrin repeat containing | krt1           | 0.99          |
| Notch 1                        | notch1         | 1.02          |
| Platelet endothelial aggregation receptor 1 | pear1 | 0.99 |
| Ras homolog gene family, member J | rhoj         | 1.02          |
| Tumor necrosis factor, alpha-induced protein 1 (endothelial) | tnfai1 | 0.99 |
| Vascular endothelial growth factor C | vegfc | 1.04          |
| Bone morphogenetic protein 4   | bmp4           | 0.99          |
| Bone morphogenetic protein 6   | bmp6           | 1.01          |

| Table 2. Altered transcripts with a link to apoptosis. |
|---------------------------------|----------------|----------------|
| **Anti-apoptotic**              | **Pro-apoptotic** |
| **Pathway**                     | **Transcript** | **HGERT/HG** | **HG/NG** | **Transcript** | **HGERT/HG** | **HG/NG** |
| AKT/Bad                         | pik3r1         | 1.03          | Caspase   | hpi1         | 1.05          |
| AKT/FRAP1                       | ddit4i         | 0.97          | Cell cycle| maged1       | 1.01          |
| BLK                             | elf2           | 0.99 1.01     | Cell cycle/CDK | ccni | 1.01 |
| Caspase                         | hspe1          | 0.99          | Cell proliferation | pdc7 | 1.02 0.99 |
| Caspase                         | ifi6           | 1.13          | Cell proliferation | ubn1 | 1.02 |
| Cell proliferation              | furin          | 1.02          | DNA repair | rm2b | 0.98 |
| DNA repair                      | acxr5          | 1.01          | FOX       | fox3         | 1.01 0.99 |
| FOX                             | foxc1          | 1.01          | FOX       | foxp1        | 1.01 |
| Impedes cyt c release           | gsn            | 1.03          | HER-2/NEU | casc4        | 0.99 1.01 |
| JNK/SAPK                       | mbip           | 0.98          | JNK/SAPK  | mapk3        | 0.98 |
| p38 MAP kinase                  | stk39          | 0.98          | JNK/SAPK  | sos1         | 1.06 0.94 |
| PS3/IXAP inhibition             | notch1         | 1.02          | MYC family | mxd4 | 1.02 0.98 |
| RAS                             | rsu1           | 0.99          | PS3/CDK   | ccnk         | 1.01 |
| RAS                             | rhob           | 1.02 0.97     | PS3       | rybp         | 1.01 0.99 |
| RAS                             | rhoj           | 1.02          | PS3       | tp53b2p2     | 1.01 |
| RAS                             | rab3b          | 1.07          | PS3       | tbrp1        | 1.02 0.98 |
| TGFβ                             | acvr2a         | 0.99          | PS3       | tp53i11      | 1.02 0.98 |
| TGFβ                             | bmp6           | 1.01          | RAS       | rassf2       | 1.01 1.03 |
| eng                             | 1.01 0.98      | WNT          | hbp1       | 0.99 |
| atrn3                           | 0.99           | dap          | 1.01          |
| pdc6                            | 0.99           | serinc3      | 1.01 0.99 |
| socs3                           | 1.01           | sox4         | 1.01 0.99 |
| txndc5                          | 1.03           | lyn          | 1.02 0.99 |

doi:10.1371/journal.pone.0065741.t001
doi:10.1371/journal.pone.0065741.t002
diabetes onset, insulin signaling and production of adhesion molecules/nitric oxide.

Of particular interest are changes in the TCA cycle and electron transport chain, changes of transcripts are shown in table 4. Pyruvate dehydrogenase (PDH) complex transfers the acetyl group of pyruvate to coenzyme A prior to the citric acid cycle. A very slight up regulation with HG/NG for pyruvate dehydrogenase (lipoamide) beta (pdhb), encoding the E1 beta subunit responsible for pyruvate dehydrogenase activity was observed. Branched-chain alpha-keto acid dehydrogenase complex (BCKD), analogous to the PDH complex, is an inner-mitochondrial enzyme complex responsible for the degradation of branched-chain amino acids (e.g. isoleucine, leucine, and valine). It converts \( \alpha \)-keto acids to acyl-CoA + CO₂ and requires thiamine pyrophosphate (TPP), FAD, NAD⁺, lipoate and coenzyme A as cofactors. BCKD complex contains 24 core transacylase (E2) subunit and associated decarboxylase (E1), dehydrogenase (E3) and regulatory subunits. The lipoamide acyltransferase (or transacylase) E2 subunit component of BCKD is encoded by dihydrolipoamide branched chain transacylase E2 (dbt). DBT was slightly up regulated with HGERT/HG. Succinate CoA synthetase converts succinyl CoA and ADP to succinate and ATP or GTP. Succinate-CoA ligase, ADP-forming, beta subunit (sucld2) was down regulated with HGERT/HG, and up regulated with HG/NG. Transcripts coding for other subunits such as sucld1 (\( \gamma \)subunit) and sucld2 (\( \beta \) subunit) were not affected by treatments. In the next reaction in the citric acid cycle, succinate dehydrogenase converts succinate to fumarate in an oxidation step. Succinate dehydrogenase is unique amongst citric acid enzymes, in that it is a nonheme iron protein located in the inner mitochondrial membrane, directly linked to electron transport. Two electrons from FADH₂ are transferred to FeS clusters on the enzyme which are in turn transferred to ubiquinone (coenzyme Q) and then molecular oxygen. Fumarase then converts fumarate to malate, which is in turn oxidized to oxaloacetate by malate dehydrogenase, using the reduction of NAD⁺ to NADH. Ubiquinone binds in a gap between subunits B, C, and D. Succinate dehydrogenase (sdh) consists of 2 hydrophilic subunits (A, B) and 2 hydrophobic membrane anchor subunits (C, D) with phospholipid binding sites for cardiolipin (CL) and phosphatidylethanolamine (PE). Transcripts coding for the hydrophilic domains (sdha, sdhb) were not affected. Succinate dehydrogenase complex, subunit C and D (sdhc and sdhd) were down regulated with HGERT/HG, and up regulated with HG/NG.

Electron transport occurs in the inner mitochondrial membrane via enzymatic reactions utilizing electron donors and acceptors. It is responsible for generation of ATP from products of the TCA cycle, fatty acid oxidation and amino acid oxidation. This pathway is tied to oxidative stress (and hyperglycemia via excess glucose equivalents entering the mitochondrial machinery) as a small percentage of electrons ‘leak out’ resulting in superoxide formation. Numerous transcripts involved in electron transport (11) had slight down regulation with HGERT/HG, five of these were oppositely regulated with HG/NG (Table 2). Transcripts were changed in all 5 electron transport chain complexes. In complex I, NADH dehydrogenase, the subunits ubiquinone 1 alpha, subcomplexes 4 (ndufa4) and 12 (ndufa12) were down regulated with HGERT/HG. Ndufa4 was up regulated with HG/NG. Overactivity of the mitochondrial respiratory chains occurs during hyperglycemia [56], increasing transcription of complex II. This

| Pathways regulated by exposure to high glucose | Z Score |
|----------------------------------------------|---------|
| TGF Beta Signaling Pathway                    | 3.95    |
| Benzo[a]pyrene metabolism                     | 3.35    |
| Pentose and glucuronate interconversions      | 3.26    |
| Glycosylphosphatidylinositol(GPI)-anchor biosynthe | 3.07    |
| Diurnally regulated genes with circadian orthologs | 3.05    |
| Prostate cancer                               | 2.92    |
| Sphingolipid metabolism                       | 2.75    |
| Pathways in cancer                            | 2.58    |
| Antigen processing and presentation           | 2.48    |
| Caffeine metabolism                           | 2.44    |

| Pathways regulated by erythritol during exposure to high glucose | Z Score |
|------------------------------------------------------------------|---------|
| Chronic myeloid leukemia                                         | 4.03    |
| Citrate cycle (TCA cycle)                                        | 3.88    |
| Delta-Notch Signaling Pathway                                    | 3.78    |
| Prostate cancer                                                 | 3.24    |
| Androgen Receptor Signaling Pathway                              | 3.09    |
| TGF-beta Receptor Signaling Pathway                              | 2.86    |
| Glutathione metabolism                                          | 2.77    |
| Glucuronidation                                                  | 2.61    |
| B cell receptor signaling pathway                                 | 2.48    |
| G13 Signaling Pathway                                            | 2.42    |

Table 3. Top 10 pathways regulated by exposure of HUVECs to high glucose (HG effect) or to erythritol during exposure to high glucose (HGERT effect).
Mechanisms of Endothelial Protection by Erythritol

In this study, we investigated the mechanisms by which erythritol protects endothelial cells during exposure to high glucose. Erythritol (ERT) was shown to prevent the onset and development of endothelial dysfunction in the diabetic rat, as demonstrated by the reduction of superoxide production and the upregulation of antioxidant genes. The protective effect of ERT was associated with the downregulation of proinflammatory genes and the upregulation of genes involved in angiogenesis and proliferation.

Table 4. Transcripts changed in citric acid cycle and electron transport system.

| Complex                  | Transcript   | HGERT/HG  | HG/NG  |
|--------------------------|--------------|-----------|--------|
| Pyruvate dehydrogenase   | pdhb         | 1.01      | 1.01   |
| Succinate CoA synthetase  | succ2        | 0.99      | 1.01   |
| Succinate dehydrogenase  | sdhc         | 0.96      | 1.02   |
| Complex I NADH dehydrogenase | ndufa4      | 0.99      | 1.02   |
| Complex II Succinate dehydrogenase | sdhc | 0.96 | 1.02 |
| Complex III Cytochrome bc1 (uqcrb) | qcr9 (uqcr, uqcr10) | 0.99 | 1.01 |
| Complex IV cytochrome c oxidase | cox5b | 0.98 |      |
| Complex V ATP synthase   | atp5e        | 0.99      | 1.01   |
|                          | atp5o        | 0.99      | 1.01   |

Regulated with HG/NG; atp5o was very slightly down regulated with HGERT/HG. ATP synthase, H⁺ transporting, mitochondrial F₁ complex, subunit G (atp5g) was slightly up regulated with HG/NG only.

Table S1 Effect of pre/co incubation with 5 mM erythritol (ERT) on HUVECs cultured in normal glucose (NG, 7 mM) or high glucose (HG, 30 mM) on eicosanoids.

Supporting Information
concentrations in cell pellets and culture medium. Data are expressed as means ± standard error of three independent experiments. *p<0.05 compared to NG; **p<0.05 compared to HG.

(DOCX)

Acknowledgments

We thank Christophe Morisseau, Department of Entomology and U.C. Davis Cancer Center, University of California Davis, CA for technical assistance in measuring eicosanoids and oxy lipsins in HUVEC cells. We also thank the Bioinformatics Maastricht (BigCAT) department members: Chris Ewelo, Maalgi Jaillard, and Lars Eijssen.

Author Contributions

Conceived and designed the experiments: DB GdH A. Berger. Performed the experiments: DB HD. Analyzed the data: DB GdH A. Bast HD BH. Contributed reagents/materials/analysis tools: DB GdH A. Bast HD BH. Wrote the paper: DB GdH A. Bast A. Berger PdC.

References

1. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813–820.
2. Ramsamy R, Fang Yan S, Schmidt AM (2005) The RAGE axis and endothelial dysfunction: Maladaptive roles in the diabetic vasculature and beyond. Trends Cardiovasc Med 15: 237–243.
3. Furchgott RF, Jothianandan D (1991) Endothelium-Dependent and Independent Vasodilatation Involving Cyclic GMP. Relaxation Induced by Nitric Oxide, Carbon Monoxide and Light. Journal of Vascular Research 28: 52–61.
4. Greive DJ, Avella MA, Botham KM, Elliott J (1998) Effects of chylomicrons remnants on endothelium-dependent relaxation of rat aorta. European Journal of Pharmacology 348: 181–190.
5. Praticò D (2003) Antioxidants and endothelial protection. Atherosclerosis 181: 215–224.
6. Ceriello A (2003) New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care 26: 1589–1596.
7. Bertn WO, Borzelleca JF, Flammar G, Munro IC (1996) Erythritol: a review of biochemical and toxicological studies. Regul Toxicol Pharmacol 24: S191–S197.
8. Yokoawasai T, Kim HV, Cho EJ (2002) Erythritol ameliorates the diabetic oxidative stress through glucose metabolism and lipid peroxidation in streptozocin-induced diabetic rats. J Agric Food Chem 50: 5485–5489.
9. Munro IC, Berntn WO, Borzelleca JF, Flammar G, Lynch BS, et al. (1998) Erythritol: an interpretive summary of biochemical, metabolic, toxicological and clinical data. Food and Chemical Toxicology 36: 1139–1174.
10. Noda K, Nakayama K, Oku T (1994) Serum glucose and insulin levels and erythritol balance after oral administration of erythritol in healthy subjects. Nippon J Clin Nutr 49: 296–292.
11. den Hartog GJ, Boots AW, Adam-Perrot A, Broun F, Verkoeyen JW, et al. (2010) Erythritol is a sweet antioxidant. Nutrition 26: 449–450.
12. den Hartog GJM, Boots AW, Harven GRMM, van der Vijgh WJF, Bast A (2003) Lack of inhibition of endothelial nitric oxide synthase in the isolated rat aorta by deoxonol. Toxicol In Vitro 17: 165–167.
13. Paupayt, JBG, t Hoen PAC, Voss HP, Bast A, Timmerman H, et al. (1999) Nitric oxide synthase inhibition by dimaprit and dimaprit analogues. British Journal of Pharmacology 127: 521–534.
14. Uker S, McKernon PP, Bayramutun U (2003) Vitamins reverse endothelial dysfunction through regulation of eNOS and NADPH oxidase activities. Hypertension 41: 534–539.
15. Rüthe TR, Leikert J, Vollmar AM, Dirsch VM (2003) Application of 4,5-diaminofluorescein to reliably measure nitric oxide released from endothelial cells in vitro. Biol Prog Online 3: 136–142.
16. Liu JY, Li N, Yang J, Li N, Qiu H, et al. (2010) Metabolic profiling of murine peritoneal macrophages in response to doxorubicin. Toxicology 17: 142–146.
17. Yang J, Schmelzer K, Georgi K, Hammock BD (2009) Quantitative profiling of prostanoids and thromboxane plus prostaglandins in human umbilical vein endothelial cells. Journal of Pharmacology and Experimental Therapeutics 331: 700–705.
18. Lundstrom S, Yang J, Kulberg J, Thumberg S, Gadvelin G, et al. (2012) Allergic asthmatics show divergent lipid mediator profiles from healthy controls and exploring biological pathways with PathVisio. BMC Bioinformatics 9: 399.
48. Tang DG, DiGio CA, Razza R, Horn KV (1995) Transcriptional activation of endothelial cell integrin alpha v by protein kinase C activator 12(S)-HETE. J Cell Sci 108 (Pt 7): 2629–2644.

49. Simionescu N (1980) Prelesional changes of arterial endothelium in hyperlipoproteinemic atherogenesis. In: Simionescu N, Simionescu M, editors. Endothelial Cell Biology in Health and Disease. New York: Plenum Press. pp. 385–429.

50. Oguro A, Fujita N, Imaoka S (2009) Regulation of soluble epoxide hydrolase (sEH) in mice with diabetes: high glucose suppresses sEH expression. Drug Metab Pharmacokinet 24: 438–445.

51. Moran JH, Nowak G, Grant DF (2001) Analysis of the toxic effects of linoleic acid, 12,13-cis-epoxyoctadecenoic acid, and 12,13-dihydroxyoctadecenoic acid in mice with diabetes: high glucose suppresses sEH expression. Drug Metab Pharmacokinet 24: 438–445.

52. Sorescu GP, Sykes M, Weiss D, Platt MO, Saha A, et al. (2003) Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. J Biol Chem 278: 31128–31135.

53. Bhasin M, Yuan L, Keskin DB, Otu HH, Libermann TA, et al. (2010) Bioinformatic identification and characterization of human endothelial cell-restricted genes. BMC Genomics 11: 342.

54. Nanda N, Bao M, Lin H, Clauser K, Komuves L, et al. (2005) Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation. J Biol Chem 280: 24680–24689.

55. Su AJ, Cooke MP, Ching KA, Hakak Y, Walker JR, et al. (2002) Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A 99: 4465–4470.

56. Chen J, Li Y, Lavigne JA, Trush MA, Yager JD (1999) Increased mitochondrial superoxide production in rat liver mitochondria, rat hepatocytes, and HepG2 cells following ethinyl estradiol treatment. Toxicological Sciences 51: 224–235.

57. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408: 239–247.

58. Horn D, Al-Ali H, Barrientos A (2008) Cmc1p is a conserved mitochondrial twin CX9C protein involved in cytochrome c oxidase biogenesis. Mol Cell Biol 28: 4354–4364.

59. Weseler AR, Rajters EJR, Drinij-Reijnders MJ, Reesink KD, Haenen GRMM, et al. (2011) Pleiotropic Benefit of Monomeric and Oligomeric Flavanols on Vascular Health - A Randomized Controlled Clinical Pilot Study. PLoS One 6: e20460.